Cancer Screening, Cervical Cancer, Cervical Intraepithelial Neoplasia, Cytology, DNA Methylation, Human Papillomavirus Infection
Conditions
Brief summary
Cervical cancer represents one of the foremost causes of cancer-related morbidity and mortality among women worldwide. Given the current limitations, such as the low specificity of human papillomavirus (HPV) testing and the relatively low sensitivity of cytological examinations, there is a pressing need for a novel, non-invasive, safe, and precise screening method. This study aims to undertake a multicentre, real-world investigation, incorporating at least 10 sub-centres and enrolling 30,000 participants. Histopathological examination results will serve as the 'gold standard' for evaluating the screening efficacy of human PAX1 and JAM3 gene methylation assays (PAX1m/JAM3m), HPV testing, and cytological examinations. Furthermore, the study seeks to elucidate the relationship between DNA methylation levels and persistent HPV infection, while also assessing the applicability of PAX1m/JAM3m across diverse clinical settings. By focusing on alterations in DNA methylation levels within cervical exfoliated cells as the primary research trajectory, this study aspires to furnish novel insights and theoretical foundations for the prevention and management of cervical cancer, targeting PAX1m/JAM3m. The ultimate objective is to facilitate the clinical implementation of an enhanced cervical cancer screening protocol, thereby addressing the deficiencies of current screening methodologies, achieving greater precision in cervical cancer screening, and effectively reducing the incidence of cervical cancer while mitigating the risks of overdiagnosis and overtreatment.
Interventions
DIAGNOSTIC_TESThuman PAX1 and JAM3 gene methylation assays (PAX1m/JAM3m)
PAX1m/JAM3m, with or without HPV testing and cytological pathology for cervical cancer screening
Sponsors
Lei Li
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Aged 18 years or older * With uterine cervix intact * Given consents to participate the study * With detailed follow-up outcomes
Exclusion criteria
* Not meeting all of the inclusion criteria
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants with histopathological diagnosis of grade 2 cervical intraepithelial neoplasia (CIN) or worse (CIN2+) | 1 year | Including CIN2, CIN3, adenocarcinoma in situ and invasive cervical carcinoma |
| Number of participants with histopathological diagnosis of grade 3 cervical intraepithelial neoplasia (CIN) or worse (CIN3+) | 1 year | Including CIN3, adenocarcinoma in situ and invasive cervical carcinoma |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants with histopathological diagnosis of invasive cervical carcinoma | 1 year | Including invasive cervical carcinoma of various subtypes |
Countries
China
Contacts
Primary ContactLei Li, M.D.
Outcome results
None listed